Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the popular diabetes and obesity treatments continue to improve, federal regulators said Friday.

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.

Nikki Laine has been taking the weight-loss drug Mounjaro for just over three weeks and has described it as "life-changing" after losing 1st st and 2lb (7.6kg). Mounjaro – also known as Tirzepatide – is an injectable prescription which contributes to weight loss when taken alongside a healthy diet and regular exercise.

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy of the weight-loss medicines it mailed to patients.

All doses of Novo's diabetes treatment Ozempic and weight-loss drug Wegovy were listed as available on the FDA's website in October, but the treatments were not taken off the offi

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S. Food and Drug Administration (FDA).

A bipartisan group of U.S. state and territory attorneys general is pressing the FDA to take prompt action against those threatening public health by marketing counterfeit forms of branded weight loss medications developed by Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY).